Cargando…
Clinical features and treatment of bone marrow metastasis
Bone marrow metastasis (BMM) refers to the metastasis of malignant tumours originating from nonhematopoietic tissues to the bone marrow. The nonhematopoietic malignant tumour cells metastasize to the bone marrow via heterogeneous dissemination or direct invasion to form metastases and the bone marro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320432/ https://www.ncbi.nlm.nih.gov/pubmed/37415634 http://dx.doi.org/10.3892/ol.2023.13918 |
_version_ | 1785068452233347072 |
---|---|
author | Yang, Hongliang He, Feng Yuan, Tian Xu, Wen Cao, Zeng |
author_facet | Yang, Hongliang He, Feng Yuan, Tian Xu, Wen Cao, Zeng |
author_sort | Yang, Hongliang |
collection | PubMed |
description | Bone marrow metastasis (BMM) refers to the metastasis of malignant tumours originating from nonhematopoietic tissues to the bone marrow. The nonhematopoietic malignant tumour cells metastasize to the bone marrow via heterogeneous dissemination or direct invasion to form metastases and the bone marrow is infiltrated by tumour cells, resulting in the destruction of its structure and the development of haematopoietic disorders. In the present study, the clinical characteristics, prognosis and treatment of BMMs were investigated. The main clinical manifestations were moderate anaemia and thrombocytopenia. Out of 52 cases, a total of 18 patients were not treated and the remaining patients underwent chemotherapy, radiotherapy, surgery or autologous stem cell transplantation in the Affiliated Tumour Hospital of Tianjin Medical University from September 2010 to October 2021. The primary tumours of bone marrow metastatic cancer were usually neuroblastoma and tumours originating from the breast and stomach. When bone metastases occur, patients are not necessarily accompanied by BMMs. In the present study, bone metastases occurred mainly in patients with breast and prostate cancers. The median overall survival of patients treated with antitumor therapy was significantly higher than that of untreated patients (11.5 vs. 3.3 months P<0.01). For patients with BMM, it is of great importance to actively evaluate the patient's condition and select the appropriate treatment plan for improving their prognosis. |
format | Online Article Text |
id | pubmed-10320432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-103204322023-07-06 Clinical features and treatment of bone marrow metastasis Yang, Hongliang He, Feng Yuan, Tian Xu, Wen Cao, Zeng Oncol Lett Articles Bone marrow metastasis (BMM) refers to the metastasis of malignant tumours originating from nonhematopoietic tissues to the bone marrow. The nonhematopoietic malignant tumour cells metastasize to the bone marrow via heterogeneous dissemination or direct invasion to form metastases and the bone marrow is infiltrated by tumour cells, resulting in the destruction of its structure and the development of haematopoietic disorders. In the present study, the clinical characteristics, prognosis and treatment of BMMs were investigated. The main clinical manifestations were moderate anaemia and thrombocytopenia. Out of 52 cases, a total of 18 patients were not treated and the remaining patients underwent chemotherapy, radiotherapy, surgery or autologous stem cell transplantation in the Affiliated Tumour Hospital of Tianjin Medical University from September 2010 to October 2021. The primary tumours of bone marrow metastatic cancer were usually neuroblastoma and tumours originating from the breast and stomach. When bone metastases occur, patients are not necessarily accompanied by BMMs. In the present study, bone metastases occurred mainly in patients with breast and prostate cancers. The median overall survival of patients treated with antitumor therapy was significantly higher than that of untreated patients (11.5 vs. 3.3 months P<0.01). For patients with BMM, it is of great importance to actively evaluate the patient's condition and select the appropriate treatment plan for improving their prognosis. D.A. Spandidos 2023-06-16 /pmc/articles/PMC10320432/ /pubmed/37415634 http://dx.doi.org/10.3892/ol.2023.13918 Text en Copyright: © Yang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Yang, Hongliang He, Feng Yuan, Tian Xu, Wen Cao, Zeng Clinical features and treatment of bone marrow metastasis |
title | Clinical features and treatment of bone marrow metastasis |
title_full | Clinical features and treatment of bone marrow metastasis |
title_fullStr | Clinical features and treatment of bone marrow metastasis |
title_full_unstemmed | Clinical features and treatment of bone marrow metastasis |
title_short | Clinical features and treatment of bone marrow metastasis |
title_sort | clinical features and treatment of bone marrow metastasis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320432/ https://www.ncbi.nlm.nih.gov/pubmed/37415634 http://dx.doi.org/10.3892/ol.2023.13918 |
work_keys_str_mv | AT yanghongliang clinicalfeaturesandtreatmentofbonemarrowmetastasis AT hefeng clinicalfeaturesandtreatmentofbonemarrowmetastasis AT yuantian clinicalfeaturesandtreatmentofbonemarrowmetastasis AT xuwen clinicalfeaturesandtreatmentofbonemarrowmetastasis AT caozeng clinicalfeaturesandtreatmentofbonemarrowmetastasis |